Targeted Therapy as Adjuvant Treatment: Should We Extrapolate from Advanced NSCLC to Earlier Stage?

Article

This past week, I saw a new patient who had just moved from another part of the country and needed long-term management of her high risk lung cancer.  A never-smoking Asian woman, she was found to have a stage IIIA lung cancer with "N2" mediastinal lymph nodes involving cancer in her mid-chest.

More targeted therapy or focus on chemotherapy after acquired resistance to a targeted therapy? How might we decide?

Article

One of the challenges we face now when a patient with a "driver mutation" like an EGFR mutation or an ALK rearrangement develops progression on a targeted therapy against that particular target is whether to continue on another agent that might work specifically against that target or switch to a less specific approach, like chemotherapy or immunotherapy, which haven't been demonstrated to be more or less effective against a specific molecularly defined subgroup.

Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Article

Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Subscribe to targeted therapy